The 12th International AIDS Society Conference on HIV Science (IAS 2023)

The Geneva patient: Another score on the HIV remission board

Audrey Abella, 20230901100000

Another HIV patient may be on the way to a cure following stem cell therapy using wild-type (WT) CCR5 donor cells for a rare and aggressive blood cancer.

Statin cuts CV risk in patients with HIV

Elvira Manzano, 20230831000000

Treatment with pitavastatin is associated with a significantly lower risk of cardiovascular (CV) events in people living with human immunodeficiency virus (HIV) as shown in the final analysis of the double-blind, placebo-controlled REPRIEVE trial presented at IAS 2023.

SNA a feasible HIV testing approach

Audrey Abella, 20230828100000

Social network testing approaches (SNA) for HIV testing may be an effective and acceptable approach to improve HIV testing in all populations, a systematic review and meta-analysis suggests.

Switching antiretroviral regimens does not help with weight loss

Jairia Dela Cruz, 20230818140000

Switching from an integrase inhibitor (INI)-based antiretroviral treatment (ART) regimen to a protease inhibitor (PI)-based regimen falls short of reversing weight gain while on the INI-based regimen, according to the results of the open-label phase IV DEFINE trial.

Circumcision may reduce HIV risk in men who have sex with men

Jairia Dela Cruz, 20230817140000

Voluntary medical male circumcision (VMMC) appears to cut the risk of contracting HIV infection among men who have sex with men (MSM), particularly those who mainly practice insertive anal sex, as shown in a study from China presented at IAS 2023.

Demedicalized delivery of PrEP possible, improves access

Stephen Padilla, 20230816120000

A peer-led demedicalized delivery of same-day HIV pre-exposure prophylaxis (PrEP) in various community centres is feasible, suggests a Philippines study presented at the recent IAS 2023.

Treating transgender patients: Are medical professionals being too “conservative”?

Meeting gender-affirming needs tied to accessing HIV services among transgender people

Stephen Padilla, 20230816110000

Having met gender-affirming care needs among transgender people is associated with accessing HIV-related services in a community-led clinic, as shown in a Philippines study presented at IAS 2023.

Risk of hypertension higher with DTG in PLWH

Audrey Abella, 20230815100000

In the secondary analysis of the NAMSAL and ADVANCE trials, first-line treatment with dolutegravir (DTG) was associated with significantly higher risks of treatment-emergent hypertension in people living with HIV (PLWH), especially in combination with tenofovir alafenamide (TAF).

Tenofovir-containing regimen sustains high viral suppression in HIV-1/HBV coinfection

Elaine Soliven, 20230809000000

Treatment with either bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG + F/TDF) resulted in similarly high and sustained rates of viral suppression in adults with HIV-1* and HBV** coinfection, according to a prespecified secondary analysis of the ALLIANCE trial presented at IAS 2023.

Two-drug HIV regimen as good as B/F/TAF

Elaine Soliven, 20230808000000

Among treatment-naïve patients with HIV-1* infection, initial treatment combination with doravirine and islatravir (DOR/ISL) was noninferior in achieving virologic suppression (HIV-1 RNA <50 copies/mL) at week 48 compared with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), according to a trial presented at IAS 2023.